Clinical trials: Vasculitis, Central Nervous System
Wegener's Granulomatosis or Microscopic Polyangiitis
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
This is a perspective, Phase IV, multi-center, single arm, open-label, interventional study in adult participants with Wegener's granulomatosis (granulomatosis with polyangiitis [GPA]) or microscopic polyangiitis.
- Trial name
- NCT02115997
- Testing
- Methylprednisolone, Prednisone, Rituximab
- Where
- 10 sites in India
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
The purpose of this study is to observe the clinical manifestation, Lab findings including chest CT scans, pathological findings and outcomes in chinese patients with pulminary vasculitis.
- Conditions
- ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, EosinphilicGranulomatosis With Polyangiitis
- Trial name
- NCT02126098
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Giant Cell Arteritis in Dependency of Elderly
Pilot Study of the Impact of Giant Cell Arteritis and Its Treatment on the Autonomy of the Elderly in the First Year of Care
Giant cell arteritis is the leading cause of vasculitis in the elderly. No work evaluates its impact on autonomy. At the diagnosis a gerontological evaluation will be carried out including the scores ADL, iADL, MNA, SF 36, SPPB…
- Trial name
- EPACAPA (NCT03961113)
- Testing
- Assessment by questionnaire
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Limoges
Rheumatic Diseases, Lupus Erythematosus, Systemic
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Background: Rheumatic diseases can affect the joints, ligaments, tendons, bones, muscles, and skin. They can also cause inflammation, damage body tissues, and change nerve signals in the brain.
- Conditions
- Rheumatic Diseases, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Arthritis
- Trial name
- NCT07829497
- Testing
- Bedside quantitative sensory testing
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Giant Cell Arteritis, Polymyalgia Rheumatic (PMR)
Giant Cell Arteritis - Ways to Precision Medicine
Long-term follow-up of aortal adverse events, as well as glucocortioid-associated adverse events in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
- Trial name
- NCT07084480
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Wuerzburg University Hospital
Bacterial Meningitis
Meningitis With Cerebral Vasculitis in Children
Purulent meningitis are life-threatening diseases in childhood. Cerebral vasculitis have been described in bacterial meningitis, but poor is known about their physiology and their impact on outcome.
- Trial name
- NCT03595761
- Where
- France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Montpellier
Vascular Access Complication, Skin and Subcutaneous Tissue Disorders
Effectiveness of a Zinc Oxide Adhesive Securement Device in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients
Study in which a zinc oxide fixation device (a product that can help protect the skin) for catheters (polyurethane tubes inserted into a vein) will be tested to reduce catheter-related complications: catheter displacement, skin…
- Conditions
- Vascular Access Complication, Skin and Subcutaneous Tissue Disorders, Phlebitis, Pain
- Trial name
- FIX-ETI (NCT06770374)
- Testing
- Control group: acrylic adhesive sutureless fixation device, Intervention Group: zinc oxide sutureless fixation device, PICC
- Where
- 2 sites in Spain
- Volunteers
- 400 people
- Sponsor
- Hospital Arnau de Vilanova
Aortitis, Giant Cell Arteritis (GCA)
TocILizumab in aorTitis in GCA (TILT)
This is a french multicenter observational study assessing safety and efficacy of biosimilar of Tocilizumab in Giant Cell Arteritis (GCA) with active aortitis, including 14 reference centers from the Groupe d'Etude Français des…
- Trial name
- TILT (NCT06271018)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)
Polymyalgia rheumatica (PMR) is a rheumatologic condition occurring in patients > 50 years old, characterized by inflammatory pain of the scapular (shoulder) and pelvic (hip) girdles.
- Trial name
- THROPIQ (NCT06609668)
- Testing
- Additional blood samples
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis
This prospective study is to explore different predictive factors for response to steroid treatment in patients with PMR and/or GCA.
- Trial name
- NCT05479448
- Testing
- Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness), Data collection for exploratory analyses of endogenous steroid hormones, Data collection for correlation between clinical defined and lab defined GC responsivness
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
Giant Cell Arteritis
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
The purpose of this study is to demonstrate the efficacy and safety of subcutaneously (s.c.) administered secukinumab 300 mg in combination with glucocorticoid taper regimen compared to placebo in combination with glucocorticoid…
- Trial name
- GigAINt (NCT05380453)
- Testing
- Secukinumab 300 mg, s.c.
- Where
- 25 sites in Germany
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus
The purpose of this study is to determine whether Libman-Sacks endocarditis (inflammation of the heart valves) is the cause of neuropsychiatric manifestations (stroke, transient ischemic attacks, cognitive dysfunction, seizures…
- Trial name
- NCT00858884
- Testing
- Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of New Mexico
Giant Cell Arteritis (GCA)
Cardiac Involvement in Patients With Giant Cell Arteritis
This prospective observational study aims to investigate whether patients with newly diagnosed giant cell arteritis (GCA) show signs of cardiac involvement.
- Trial name
- NCT07031284
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- University Hospital, Bonn
Lupus Erythematosus, Systemic, Systemic Vasculitis
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
The purpose of this study it to determine whether the use of a gonadotropin releasing hormone (GnRH)-agonist (depot-leuprolide acetate) during cyclophosphamide (CYC) therapy in women with rheumatic diseases will provide greater…
- Conditions
- Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis
- Trial name
- LUPRON (NCT01257802)
- Testing
- depot leuprolide acetate 3.75 mg
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Joseph Mccune
Giant Cell Arteritis, Acute Phase
Study of Circulating Microparticles in Giant Cell Arteritis
To demonstrate that microparticles (MPs), having a powerful procoagulant potential, are in larger amounts in the blood of patients with histologically proven giant cell arteritis (GCA), compared with patients matched for age, sex…
- Trial name
- MicroGiant (NCT02333708)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Arrhythmia, Atrial Fibrillation
Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)
To determine the benefits and risks of oral anticoagulant therapy in reducing embolic stroke and systemic emboli in patients with atrial fibrillation without rheumatic heart disease.
- Conditions
- Arrhythmia, Atrial Fibrillation, Cardiovascular Diseases, Cerebral Embolism and Thrombosis
- Trial name
- NCT00000517
- Testing
- warfarin
- Sponsor
- Massachusetts General Hospital
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Multiple Sclerosis, NMO Spectrum Disorder
China National Registry of Neuro-Inflammatory Diseases
Central nervous system (CNS) idiopathic inflammatory demyelinating diseases (IDD) are mainly diseases caused by autoimmune factors that result in CNS demyelination damage and loss.
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Clinically Isolated Syndrome, CNS Demyelinating Autoimmune Diseases
- Trial name
- CNRID (NCT05154370)
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Tiantan Hospital
ANCA Associated Systemic Vasculitis, Wegener's Granulomatosis
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
A comparison of intermittent pulsed cyclophosphamide to daily oral cyclophosphamide for the treatment of ANCA-associated systemic vasculitides with kidney involvement. Performed by the European Vasculitis Study group.
- Conditions
- ANCA Associated Systemic Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Trial name
- NCT00430105
- Testing
- cyclophosphamide
- Volunteers
- 160 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
COVID-19, Systemic Lupus Erythematosus
Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe
The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern.
- Conditions
- COVID-19, Systemic Lupus Erythematosus, Sjogren's Syndrome, Axial Spondyloarthritis
- Trial name
- Euro-COVIMID (NCT04397237)
- Where
- France
- Volunteers
- 3,100 people
- Sponsor
- Pitié-Salpêtrière Hospital